# Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

> **NCT02880228** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 11 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02880228
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-16
- **Primary completion:** 2017-07-06
- **Final completion:** 2018-07-29
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880228, "Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02880228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*